Synonym
CG-400549; CG 400549; CG400549; CG-0549; CG 0549; CG0549; Nilofabicin
IUPAC/Chemical Name
1-(3-amino-2-methylbenzyl)-4-(2-(thiophen-2-yl)ethoxy)pyridin-2(1H)-one
InChi Key
YCLREGRRHGLOAK-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
SMILES Code
O=C1C=C(OCCC2=CC=CS2)C=CN1CC3=CC=CC(N)=C3C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Nilofabicin is an enoyl-(acyl-carrier protein) reductase (FabI) inhibitor.
In vitro activity:
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.
Reference: Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. https://pubmed.ncbi.nlm.nih.gov/17420210/
In vivo activity:
In vivo activity of CG400549 was determined against systemic infections in mice. CG400549 was effective by oral or subcutaneous administration against systemic infections in mice. In a time-kill study, CG400549 at concentrations of 1 x MIC, 2 x MIC and 4 x MIC had a bacteriostatic activity during 24 h.
Reference: J Antimicrob Chemother. 2007 Sep;60(3):568-74. https://pubmed.ncbi.nlm.nih.gov/17606482/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
100.0 |
293.74 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
340.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. doi: 10.1128/AAC.01562-06. Epub 2007 Apr 9. PMID: 17420210; PMCID: PMC1913239.
2. Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother. 2007 Sep;60(3):568-74. doi: 10.1093/jac/dkm236. Epub 2007 Jul 2. PMID: 17606482.
In vitro protocol:
Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. doi: 10.1128/AAC.01562-06. Epub 2007 Apr 9. PMID: 17420210; PMCID: PMC1913239.
In vivo protocol:
Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother. 2007 Sep;60(3):568-74. doi: 10.1093/jac/dkm236. Epub 2007 Jul 2. PMID: 17606482.
1: Kim BY, Sohn YT. Solid state of CG-400549, a novel FabI inhibitor:
characterization, dissolution, transformation. Arch Pharm Res. 2011
May;34(5):775-9. doi: 10.1007/s12272-011-0511-7. Epub 2011 Jun 9. PubMed PMID:
21656363.
2: Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC.
Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor,
compared with that of other agents. Antimicrob Agents Chemother. 2007
Nov;51(11):4191-5. Epub 2007 Sep 17. PubMed PMID: 17875997; PubMed Central PMCID:
PMC2151435.
3: Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM. In vitro
activities of CG400549, a novel FabI inhibitor, against recently isolated
clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007
Jul;51(7):2591-3. Epub 2007 Apr 9. PubMed PMID: 17420210; PubMed Central PMCID:
PMC1913239.
